( 20 U.S.C. 1001 )), researchers, and other relevant stakeholders. (c) Final guidance The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall finalize the draft guidance issued under subsection (a) not later than 2 years after the date of the enactment of this Act. 6. Including antifungal biological products as qualified infectious disease products (a) In general Section 505E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355f ) is amended— (1) in subsection (a)— (A) by inserting (or, pursuant to section 351 of the Public Health Service Act, in the case of an antifungal biological product) after pursuant to section 505 for a drug